News Releases
- Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program September 21, 2022
- Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF September 19, 2022
- Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study September 12, 2022
- Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami September 8, 2022
- Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough September 1, 2022
- Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position August 23, 2022
- Algernon Pharmaceuticals Announces Closing of Private Placement August 23, 2022
- Algernon Pharmaceuticals Announces Private Placement August 18, 2022
- Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference August 3, 2022
- Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough July 28, 2022